AI for protein design.
Pushing the limits.

Scroll Down

About us

From discovery to design.

We design it from day one, revolutionizing how protein therapeutics are developed.

At Galux, we develop a pioneering protein therapeutics design platform, GaluxDesign, that uniquely integrates
artificial intelligence and physical principles.

We bring your imagined proteins to life.

Our platform

GaluxDesign: Integrating physics into AI

Our proprietary AI platform is trained to design proteins from first principles,
resulting in its modality-agnostic nature.

Its unprecedented accuracy has been demonstrated through the de novo design
of antibodies, one of the most challenging protein classes to design.

Latest stories from Galux

Galux and Celltrion Enter Strategic Partnership to Co-Develop Next-Generation Multispecific Antibodies for Autoimmune Diseases
Read More
Galux claims ‘one-day antibody design’ as it enters the global top-three AI race
Read More
AI Designs, We Validate: An Interview with Mooyoung, Head of Drug Development Center
Read More
Precision at Every Scale: Efficiency in AI-Driven De Novo Antibody Design
Read More
Galux Achieves Breakthrough by Delivering High-Affinity De Novo Antibodies from Only 50 AI Designs, Marking a New Era in Precision Protein Design
Read More
Galux and ISU Abxis Sign MOU to Collaborate on AI-Driven Drug Discovery
Read More

Join forces with Galux
to lead the next wave of drug innovation.
Together, we push boundaries
and redefine what's possible in medicine.

image